Cargando…
Reassessing the Safety Profile of Lesinurad in Combination with Xanthine Oxidase Inhibitor Therapy
INTRODUCTION: The rate of adverse renal events has been shown to be higher in patients treated with lesinurad plus a xanthine-oxidase inhibitor (XOI) than in patients treated only with a XOI. We reassessed the risks for various adverse renal events from a different perspective and devised a hypothes...
Autores principales: | Perez-Ruiz, Fernando, Jansen, Tim L., Tausche, Anne-Kathrin, Richette, Pascal, Lioté, Frédéric, So, Alexander K., Stack, Austin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393267/ https://www.ncbi.nlm.nih.gov/pubmed/30767124 http://dx.doi.org/10.1007/s40744-019-0143-9 |
Ejemplares similares
-
Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout
por: Pérez-Ruiz, Fernando, et al.
Publicado: (2019) -
Xanthine oxidase inhibitors and sepsis
por: Ramos, Maria Fátima de Paula, et al.
Publicado: (2018) -
Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout
por: Terkeltaub, Robert, et al.
Publicado: (2019) -
Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study
por: Dalbeth, Nicola, et al.
Publicado: (2019) -
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
por: Perez-Ruiz, Fernando, et al.
Publicado: (2020)